Clinical TrialMay 13, 2026, 07:02 AM
Atea Pharma to Present HCV & HEV Data at EASL Congress 2026
AI Summary
Atea Pharmaceuticals announced the acceptance of three abstracts for presentation at the European Association for the Study of the Liver (EASL) Congress 2026. These include two posters supporting their fixed-dose combination regimen for Hepatitis C Virus (HCV) and a top poster presentation of preclinical data for AT-587, their lead clinical candidate for Hepatitis E Virus (HEV). The company highlighted that these presentations underscore progress across its antiviral pipeline and reinforce the potential for a best-in-class profile for their HCV regimen and a first-in-class therapy for HEV, with AT-587 expected to advance into clinical development mid-2026.
Key Highlights
- Atea Pharmaceuticals to present 3 abstracts at EASL Congress 2026 (May 27-30).
- Preclinical data for AT-587, a lead HEV candidate, designated as a top poster presentation.
- Two posters support bemnifosbuvir and ruzasvir fixed-dose combination for HCV treatment.
- AT-587 clinical development for HEV is anticipated to begin mid-2026.
- Bemnifosbuvir and ruzasvir regimen is nearing topline results from Phase 3 C-BEYOND and C-FORWARD trials.
Price Impact
More from AVIR